retatrutide ly3437943 clinical trial results New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats As an obesity medicine physician,

Therapeutic Potential Research into DSIP's therapeutic applications has expanded considerably: Depression and Mood Disorders : Current studies investigate DSIP as a potential treatment for major depressive disorder, particularly due to its effects on sleep architecture and neurotransmitter regulation

But with peptides, there are no shortcuts

We Need More Nuanced Conversations The current conversation around GLP-1 medications is often extremely polarized: They are portrayed as miracle cures People who use them are either idolized or criticized In reality, it is more complicated than either extreme

doi: 10.1007/BF02682019

Patients who have struggled with yo-yo dieting or regained weight after lifestyle interventions often experience the strongest response to GLP-1 therapy